Company Description
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States.
The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals.
Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.
Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Michael Rowe |
Contact Details
Address: 295 Madison Avenue, Suite 2400 New York, New York 10017 United States | |
| Phone | 917 289 1117 |
| Website | eyenovia.com |
Stock Details
| Ticker Symbol | EYEN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682639 |
| CUSIP Number | 30234E104 |
| ISIN Number | US30234E1047 |
| Employer ID | 47-1178401 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael M. Rowe | Principal Financial Officer, Chief Executive Officer, President and Director |
| Dr. Tsontcho Ianchulev M.D., M.P.H., MPH | Co-Founder and Executive Director |
| Bren Kern | Chief Operating Officer |
| Norbert Lowe | Senior Vice President of Commercial Operations |
| Enrico Brambilla | Senior Vice President of Research & Development |
| Alexander Lobo | Investor Contact |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2025 | 8-K | Current Report |
| May 2, 2025 | 8-K | Current Report |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 25, 2025 | EFFECT | Notice of Effectiveness |
| Apr 25, 2025 | 424B3 | Prospectus |
| Apr 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 17, 2025 | 424B5 | Filing |
| Apr 15, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 20, 2025 | 8-K | Current Report |